Comparative Pharmacology
Head-to-head clinical analysis: CAPLYTA versus LYBALVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPLYTA versus LYBALVI.
CAPLYTA vs LYBALVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPLYTA (lumateperone) is a second-generation antipsychotic with a unique mechanism of action. It acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. It also functions as a serotonin transporter (SERT) inhibitor and has partial agonist activity at dopamine D1 receptors. Additionally, it modulates glutamate via effects on NMDA receptors and mTOR signaling.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
42 mg orally once daily, with or without food. Initiate at 42 mg/day; no dose titration required.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of lumateperone is approximately 18 hours, supporting once-daily dosing with steady state achieved within 5 days.
Terminal half-life ~20-30 hours; supports once-daily dosing.
Following oral administration of lumateperone, approximately 81% of the dose is excreted in feces (mostly as metabolites) and 12% in urine (as metabolites). Less than 1% is excreted unchanged in urine.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic